Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Reaffirmed

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research report issued on Thursday, Benzinga reports. They currently have a $7.00 price target on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 191.67% from the company’s current price. A […]

Related Keywords

Piper Sandler , Taysha Gene Therapies Inc , Dynamic Technology Lab Private Ltd , Maven Securities , Cantor Fitzgerald , Canaccord Genuity Group , Howard Capital Management Inc , Victory Capital Management Inc , Taysha Gene Therapies Company Profile , Capital Investment Advisors , Needham Company , Taysha Gene Therapies , Get Free Report , Genuity Group , Chardan Capital , Gene Therapies , Capital Management , Technology Lab Private Ltd , Investment Advisors , Taysha Gene Therapies Daily ,